A couple chatting while drinking coffee.

If you're hospitalized with COVID-19,

VEKLURY® could help speed up your recovery

Talk to a healthcare provider to find out if VEKLURY may be an option for you.

LEARN ABOUT RESULTS WITH VEKLURY

VEKLURY is a prescription medicine used to treat COVID-19 in adults and children weighing at least 3 pounds who are hospitalized; or not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death. Talk to a healthcare provider to see if VEKLURY may be an option for you.

In a clinical study, patients who were hospitalized with COVID-19 recovered 5 days faster with VEKLURY

In a study, the effectiveness of VEKLURY was compared to placebo* in 1062 adult men and women of different races and ethnic backgrounds who were hospitalized with mild-to-moderate or severe COVID-19. The median number of days to recovery for patients treated with VEKLURY was 10 days vs 15 days for patients who received placebo. Recovery referred to patients who were no longer hospitalized or hospitalized but did not require ongoing medical care for COVID-19.

The most common side effect in people receiving VEKLURY is nausea. Side effects with VEKLURY were similar to those in the group taking placebo.

*A placebo is a treatment that does not contain medication. It is used as a comparison when testing treatments.

The medians demonstrate that half of patients treated with VEKLURY recovered within 10 days while half of patients receiving placebo recovered within 15 days.

See results in hospitalized, nonhospitalized, and pediatric patients who were treated with VEKLURY

SEE RESULTS WITH VEKLURY

VEKLURY is the first and only FDA-approved COVID-19 treatment for both hospitalized and nonhospitalized patients

LEARN ABOUT VEKLURY

IMPORTANT SAFETY INFORMATION

Who should not take VEKLURY?

Do not take VEKLURY if you:

  • Are allergic to remdesivir or any of the other ingredients in VEKLURY.

What are the possible side effects of VEKLURY?

Serious side effects of VEKLURY may include:

  • Allergic reactions. VEKLURY can cause allergic reactions during or after infusion. Tell your healthcare provider right away if you get any of the following symptoms: changes to heart rate, rash, fever, nausea, sweating, shortness of breath, or wheezing, or swelling of the lips, face, or throat.
  • Increase in liver enzymes. Increases in the amount of liver enzymes are common in people who have received VEKLURY and may be a sign of liver injury. Your healthcare provider will do blood tests to check your liver enzymes before and during treatment and may stop your treatment with VEKLURY if you develop new or worsening liver problems.

The most common side effect in people receiving VEKLURY is nausea. Tell your healthcare provider if you have any side effects that bother you or do not go away.

What should I tell my healthcare provider before receiving VEKLURY?

  • All your health problems. Be sure to tell your healthcare provider if you have or have had any allergies, liver problems, or any serious illnesses.
  • If you are pregnant or breastfeeding: It is not known if VEKLURY may harm your unborn baby if taken during the first trimester. VEKLURY can pass into your breast milk. If you are pregnant or breastfeeding, discuss your options and specific situation with your healthcare provider.
  • All the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Other medicines may affect how VEKLURY works. Especially tell your healthcare provider if you are taking any medicines that contain chloroquine phosphate or hydroxychloroquine sulfate.

How is VEKLURY given?

  • Hospitalized: VEKLURY is given to you through a vein by intravenous (IV) infusion one time each day for up to 10 days. Your healthcare provider will decide how many doses you need.
  • Not hospitalized: VEKLURY is given to you through a vein by IV infusion one time each day for 3 days.

WHAT IS VEKLURY?

VEKLURY is a prescription medicine used to treat COVID-19 in adults and children weighing at least 3 pounds who are:

  • Hospitalized, or
  • Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.

Talk to a healthcare provider to see if VEKLURY may be an option for you.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch, or call 1-800-FDA-10881-800-FDA-1088.

Please see Patient Prescribing Information for VEKLURY.